Clinical high risk (CHR) for psychosis1 is an early phase that offers a unique window of opportunity for studying pathophysiology and subsequently implementing targeted interventions. The hippocampal glutamatergic dysfunction model proposes that N-methyl-D-aspartate receptor hypofunction mediates increased extracellular glutamate specifically in the left hippocampus initially, which then drives hypermetabolism and subsequent atrophy,2,3 heralding the onset of psychotic symptoms. Hippocampal hyperactivity influences downstream dopaminergic circuits resulting in positive symptoms of psychosis.4 Hippocampal atrophy predicts progression to psychosis in CHR with attenuated positive symptom psychosis-risk syndrome (APSS).5